CLASS II Device recall · Reported 13 Dec 2017 · FDA Enforcement Report

patient monitor recalled by Fukuda Denshi Co

Fukuda Denshi is recalling patient monitor, distributed nationwide in the US. The recall was initiated on 16 Oct 2017 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesall DS-8100 units manufactured and distributed worldwide.
Quantity recalled6227 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-0203-2018
FDA event ID
78441
Recalling firm
Fukuda Denshi, Tokyo, N/A
Classification
Class II
Status
Completed
Recall initiated
16 Oct 2017
FDA classified
6 Dec 2017
Reported
13 Dec 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Device Malfunction
Device type
Patient Monitors

Timeline

16 Oct 2017Recall initiated by company
6 Dec 2017Classified by FDA+51 days
13 Dec 2017Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

For the Fukuda Denshi patient monitor model DS-8100, in less than 0.003% (17) of the 6227 devices sold worldwide, a Short-term Battery Error message has appeared and has been traced back to a bad (damaged) Lithium-Ion capacitor (Short-term battery backup).

Device recalls are issued when a component, software or design fault could cause the device to fail or give wrong readings. Many are corrections applied in the field rather than physical returns.

Product as listed by the FDA

Fukuda Denshi patient monitor model DS-8100M and DS-8100N Product Usage: Use of the Fukuda Denshi DynaScope Model DS-8100N/8100M Patient Monitor is indicated in those situations where observation of one or more of the following parameters on an individual patient may be required. ECG (waveform, heart rate, ST-Level and ventricular arrhythmias), respiration, non-invasive blood pressure (NIBP), pulse rate, arterial oxygen saturation (SpO2), carboxyhemoglobin saturation (SpCO)*, methemoglobin saturation (SpMet)*, total hemoglobin concentration (SpHb)*, plethysmograph, temperature, invasive blood pressure (IBP), cardiac output, and carbon dioxide concentration (CO2). *: DS-8100M only The target populations of the system are adult, pediatric and neonatal patients with the exception of the ST segment, arrhythmia analysis, and SpHb, for which the target populations are adult and pediatric excluding neonates. These observations can include an audible and visual alarm if any of these parameters exceed values that are established by the clinician. The observations may include the individual or comparative trending of one or more of these parameters over a period of up to 24 hours. The DS-8100N/8100M Patient Monitor is indicated in situations where an instantaneous display of waveform, numeric and trended values is desired. The DS-8100N/8100M Patient Monitor is also indicated where a hard copy record of the physiological parameters, the alarms conditions or the trended values may be required.

Where it was distributed

Worldwide Distribution - US Nationwide and in the countries of UK, and Japan and via distributors in the other countries

Nationwide

Questions about this recall

Why was it recalled?

For the Fukuda Denshi patient monitor model DS-8100, in less than 0.003% (17) of the 6227 devices sold worldwide, a Short-term Battery Error message has appeared and has been traced back to a bad (damaged) Lithium-Ion capacitor (Short-term battery backup).

Which lots are affected?

all DS-8100 units manufactured and distributed worldwide.

Where was it sold?

Worldwide Distribution - US Nationwide and in the countries of UK, and Japan and via distributors in the other countries

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other Patient Monitors recalls

All 1,013